May 30, 2026 — RNews

#immunotherapy — Saturday, May 30, 2026 (3 items)

hot top new

💬 0	Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study. (linkinghub.elsevier.com)	Giovannoni G … Oh J The Lancet 2026-05-30	#clinical trial #immunotherapy #multiple sclerosis #disability progression
💬 0	Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study. (linkinghub.elsevier.com)	Nikolcheva T … Bonni A The Lancet 2026-05-30	#clinical trial #immunotherapy #neurodegeneration #neuroprotection
💬 0	Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials. (linkinghub.elsevier.com)	Hauser SL … Kappos L The Lancet 2026-05-30	#antibody #clinical trial #immunotherapy #multiple sclerosis